-
Product Insights
Gallbladder Cancer - Drugs In Development, 2024
Empower your strategies with our Gallbladder Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Gallbladder cancer symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine, and weight loss. Risk factors include overweight, age, family history, gallstones, gender, and choledochal cysts. Treatment includes surgery, chemotherapy, and radiation therapy. The Gallbladder Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Gallbladder Cancer, complete with...
-
Product Insights
Neuroendocrine Tumors - Drugs In Development, 2024
Empower your strategies with our Neuroendocrine Tumors – Drugs In Development, 2024 report and make more profitable business decisions. Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptoms include hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety, and gastric ulcer disease. Treatments include surgery, radiation therapy, and...
-
Product Insights
Primary Mediastinal B-Cell Lymphoma - Drugs In Development, 2024
Empower your strategies with our Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Primary Mediastinal B-Cell Lymphoma (PMBCL) is a distinct subtype of non-Hodgkin lymphoma predominantly affecting young adults. Originating in the mediastinum, symptoms include cough, chest pain, and difficulty breathing. Diagnosed through imaging and biopsy, PMBCL resembles large B-cells and expresses markers like CD20 and CD30. Standard treatment involves aggressive chemotherapy, often with rituximab (R-CHOP regimen), and may include radiation. Despite sharing...
-
Product Insights
Metastatic Ovarian Cancer - Drugs In Development, 2024
Empower your strategies with our Metastatic Ovarian Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Metastatic ovarian cancer results from the spread of ovarian cancer cells beyond the ovaries, commonly reaching the peritoneum, liver, lungs, and lymph nodes. Symptoms like abdominal pain, weight loss, and digestive changes may manifest. Diagnosis involves imaging, blood tests, and surgical biopsy. Staging determines treatment strategies, typically involving surgery and chemotherapy. Prognosis varies, influenced by factors such as metastatic extent and...
-
Product Insights
Non-Rhabdomyosarcoma - Drugs In Development, 2024
Empower your strategies with our Non-Rhabdomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Non-rhabdomyosarcoma refers to a group of cancers that are distinct from rhabdomyosarcoma, a type of soft tissue cancer that arises from skeletal muscle cells. Non-rhabdomyosarcoma includes various types of soft tissue sarcomas that originate in tissues such as nerves, blood vessels, fat, and connective tissues. These sarcomas can occur in different parts of the body, and their characteristics and treatment approaches vary. Common...
-
Product Insights
Laryngeal Cancer - Drugs In Development, 2024
Empower your strategies with our Laryngeal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Laryngeal cancer is a disease in which malignant (cancer) cells form in the tissues of the larynx. Most laryngeal cancers form in squamous cells, the thin, flat cells lining the inside of the larynx. Symptoms include persistent hoarseness, difficulty swallowing, sore throat, or a lump in the neck. Treatment involves a combination of surgery, radiation therapy, and chemotherapy. Early detection is crucial...
-
Product Insights
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) - Drugs In Development, 2024
Empower your strategies with our Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions. Waldenstrom macroglobulinemia, one of the malignant monoclonal gammopathies, is a chronic, indolent, lymphoproliferative disorder. It is characterized by the presence of a high level of a macroglobulin (immunoglobulin M [IgM]), elevated serum viscosity, and the presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenström macroglobulinemia is considered to be a lymphoplasmacytic lymphoma, as defined by the Revised European American...
-
Product Insights
Cutaneous T-Cell Lymphoma - Drugs In Development, 2024
Empower your strategies with our Cutaneous T-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Cutaneous T-cell lymphoma (CTCL) is a rare type of cancer that begins in white blood cells called T cells (T lymphocytes). These cells normally help body's germ-fighting immune system. In cutaneous T-cell lymphoma, the T cells develop abnormalities that make them attack the skin. Originating in T lymphocytes, it causes skin alterations like red, scaly patches or itchy plaques, progressing slowly...
-
Product Insights
Metastatic Adenocarcinoma of The Pancreas - Drugs In Development, 2024
Empower your strategies with our Metastatic Adenocarcinoma of The Pancreas – Drugs In Development, 2024 report and make more profitable business decisions. Metastatic adenocarcinoma is a cancer that originates in glandular cells (mucus-secreting cells) such as milk ducts, the digestive tract, or lungs and has spread or metastasized beyond the tissue in which it began. Adenocarcinomas can spread at any stage of the disease or they can lay dormant for an extended period of time before recurring in a distant location....
-
Product Insights
Anal Cancer - Drugs In Development, 2024
Empower your strategies with our Anal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, and narrowing of stool. Predisposing factors include HPV infections, smoking, and lowered immunity. The Anal Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Anal...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.